Global biopharmaceutical firm Harbour BioMed (HBM) announced on Thursday the completion of a Series B+ round of financing at $75 million to accelerate the advancement of its clinical-stage compounds and next-generation biotherapeutics for treating cancer and immunological diseases.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
